Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer

Wang, Xuejian; Jiang, Wenyan; Du, Yanmei; Zhu, Dejun; Zhang, Jian; Fang, Chunyan; Fang, Yan; Chen, Zhe-Sheng

doi:10.1016/j.drup.2022.100884

Cited by 24 publications

(8 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the TME, exosomal miRNAs promote tumor angiogenesis, cell migration 74 , invasion, metastasis 75 , 76 and drug resistance 77 – 79 by reprogramming M2-like TAMs. Anticancer medication resistance is strongly associated with abnormal expression of PI3K/Akt, STAT3, MAPK, and other signaling pathways 80 . Exosomes from TAMs can modify these signaling pathways to modulate therapeutic resistance.…”

Section: M2-like Tams Have Involvement In Promoting Multidrug Resista...mentioning

confidence: 99%

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance

Wang,

Chen

et al. 2024

npj Precis. Onc.

View full text Add to dashboard Cite

Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute essential components of the TME. M2-like TAMs are essential in facilitating tumor metastasis as well as augmenting the drug resistance of tumors. This review encapsulates the mechanisms that M2-like TAMs use to promote tumor drug resistance. We also describe the emerging therapeutic strategies that are currently targeting M2-like TAMs in combination with other antitumor drugs, with some still undergoing clinical trial evaluation. Furthermore, we summarize and analyze various existing approaches for developing novel drugs that target M2-like TAMs to overcome tumor resistance, highlighting how targeting M2-like TAMs can effectively stop tumor growth, metastasis, and overcome tumor drug resistance.

show abstract

Section: M2-like Tams Have Involvement In Promoting Multidrug Resista...mentioning

confidence: 99%

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance

Wang,

Chen

et al. 2024

npj Precis. Onc.

View full text Add to dashboard Cite

show abstract

“…FGFR kinase inhibitors (including pemigatinib) are no exception, and patients acquire resistance due to acquisition of amino acid mutations or activation of alternative pathways. 46 In this situation, combination therapy is often required to produce better therapeutic effects.…”

Section: Resultsmentioning

confidence: 99%

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma

Chu,

Zhang,

Zhou

et al. 2023

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…HR-/Her2- is associated with worse survival. Compared to patients with HR+/HER2− disease, patients with ER+/HER2+ disease had a lower odds to develop radiographic ascites ( 33 , 34 ). The sensitivity to endocrine therapy was higher in HR+ patients than in HR− patients, especially in the HR+/HER2− group ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer

Yang¹,

Zhang²,

Li³

et al. 2022

Gland Surg

View full text Add to dashboard Cite

Background: Breast cancer is a highly heterogeneous disease. Early-stage, non-metastatic breast cancer is considered curable after definitive treatment. Early detection of tumor recurrence and metastasis through sensitive biomarkers is helpful for guiding clinical decision-making and early intervention in second-line treatment, which could improve patient prognosis and survival.Methods: In this real-world study, we retrospectively analyzed 82 patients with stages I to III breast cancer who had been analyzed by molecular residual disease (MRD) assay. A total of 82 tumor tissues and 224 peripheral blood samples were collected and detected by next-generation sequencing (NGS) based on a 1,021-gene panel in this study.Results: MRD positivity was detected in 18 of 82 patients (22.0%). The hormone receptor−/human epidermal growth factor receptor 2+ (HR−/HER2+) subgroup had the highest postoperative MRD detection rate at 30.8% (4/13). The BRCA2 and SLX4 genes were significantly enriched in all patients in the MRD positive group and FGFR1 amplification was significantly enriched in the MRD negative group with HR+/ HER2−. The number of single nucleotide variants (SNVs) in tissue samples of MRD-positive patients was higher than that of MRD-negative patients (11.94 vs. 8.50 SNVs/sample). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that there was a similar biological function of the tumormutated genes in the 2 MRD status groups.Conclusions: This real-world study confirmed that patient samples of primary tumor tissue with different MRD status and molecular subtypes had differential genetic features, which may be used to predict patients at high risk for recurrence.

show abstract

Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer

Cited by 24 publications

References 139 publications

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma

The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer

Contact Info

Product

Resources

About